Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Siddharth Shah

Clinical Cardiac Electrophysiology Indianapolis, IN Medical Doctor

NPI 1518341940 CMS profile 9220952

1800 N Capitol Ave # E371, Indianapolis, IN 46202

Open in the dashboard

General payments

$21,615

127 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Siddharth Shah of Indianapolis, IN is reported in the CMS Open Payments database as having received $21,615 across 127 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,109 16
2024 General $491 7
2023 General $12,490 53
2022 General $5,870 45
2021 General $633 5
2020 General $23 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Siddharth Shah
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Siddharth Shah were reported at $2,109. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Siddharth Shah Clinical Cardiac Electrophysiology median Middle half National median
2019 $0 $2,361 $585–$8,260 $163
2020 $23 $993 $247–$4,351 $114
2021 $633 $1,185 $326–$4,739 $132
2022 $5,870 $2,073 $554–$6,789 $149
2023 $12,490 $2,568 $759–$8,159 $160
2024 $491 $2,557 $703–$7,403 $164
2025 $2,109 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Biotronik Inc. $8,512 39 payments
  2. Medtronic, Inc. $5,330 35 payments
  3. Boston Scientific Corporation $2,580 12 payments
  4. Medical Device Business Services, Inc. $2,537 5 payments
  5. Abbott Laboratories $2,128 14 payments
  6. Biosense Webster, Inc. $344 14 payments
  7. Atricure, Inc. $68 2 payments
  8. EMD Serono, Inc. $39 2 payments
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $25 1 payment
  10. Cardiva Medical, Inc. $23 1 payment
  11. Other $27 2 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Travel and Lodging $14,422 35 payments
  2. Food and Beverage $4,371 84 payments
  3. Grant $1,500 1 payment
  4. Education $1,322 7 payments
Products named General payments · program years 2020–2025
  1. Carto 3 $2,893 19 payments
  2. Micra $2,140 20 payments
  3. AVEIR $1,706 9 payments
  4. Edora 8 DR-T $841 5 payments
  5. Acticor 7 VR-T DX $841 5 payments
  6. Rivacor 7 DR-T $841 5 payments
  7. BioMonitor $841 5 payments
  8. Solia $766 3 payments
  9. Arctic Front $367 1 payment
  10. AZURE XT DR MRI SURESCAN $284 6 payments
  11. Other $1,287 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

665

Median for Cardiology: 2,533

Drug cost

$229,788

Median for Cardiology: $485,213

Branded share of claims

32.6%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 154 $196,985
Xarelto Rivaroxaban Brand 19 $24,608
Metoprolol Succinate Generic 221 $3,467
Amiodarone Hcl Generic 75 $1,722
Flecainide Acetate Generic 32 $1,376
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 30 $582
Sotalol Sotalol Hcl Brand 14 $290
Omeprazole Generic 14 $173
Metoprolol Tartrate Generic 21 $154
Carvedilol Generic 23 $118

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$126,053

Medicare's payments for the services billed

Medicare patients

1,121

Average age 76

Services billed

2,252

549 women, 572 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Atrial fibrillation 46%
Ischemic heart disease 44%
Heart failure 43%
Chronic kidney disease 40%
Diabetes 36%
COPD 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

127 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record